Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anatumomab mafenatox (ABR-214936), a 73 KDa recombinant protein, targets the tumor-associated antigen 5T4 commonly expressed in malignancies. It is a conjugate comprising a modified form of SEA linked to a murine Fab. The primary adverse effects of Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Anatumomab mafenatox (ABR-214936), a 73 KDa recombinant protein, targets the tumor-associated antigen 5T4 commonly expressed in malignancies. It is a conjugate comprising a modified form of SEA linked to a murine Fab. The primary adverse effects of Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness [1]. |
Synonyms | ABR-214936 |
Molecular Weight | N/A |
CAS No. | 1370261-50-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Anatumomab mafenatox 1370261-50-9 ABR-214936 inhibitor inhibit